August 3 2013 – Ambrisentan found ineffective against idiopathic pulmonary fibrosis

1. Ambrisentan is ineffective in delaying disease progression in idiopathic pulmonary fibrosis (IPF).

2. Compared to placebo, Ambrisentan is associated with increased risk of disease progression and respiratory hospitalization.

Evidence rating level: 1 (Excellent)

Study rundown: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive form of fibrotic interstitial lung disease with unknown etiology. IPF is a diagnosis of exclusion, and has a median survival of 3 years after diagnosis. There are no approved drug therapies in the US that have been repeatedly proven efficacious. Therefore, there is a great deal of interest in potential therapies for IPF.

Read the entire article at:

For more information about Idiopathic Pulmonary Fibrosis please visit our website and don’t forget to like us on


This entry was posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized and tagged , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>